American Society of Clinical OncologyDuration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

The International Duration of Adjuvant Chemotherapy (IDEA) collaboration investigated whether 3-month adjuvant chemotherapy treatment can be given for colon cancer without compromising efficacy, as six-month adjuvant chemotherapy with a fluoropyrimidine and oxaliplatin doublet is an option for high-risk stage II colon cancer. Here are the results.

M3Five Foods as Good as Medicine

The Healthy Eating Index (HEI) is a diagnostic indicator (0-100) of how well Americans conform to dietary advice, and the latest US numbers in 2015 were low: 59. Older Americans were better than young, but the fact remains we could all do better with the choices we’re making in our daily intake. Here are five […]

American Society of HematologyASH/ISTH/NHF/WFH 2021Guidelines on the Management of von Willebrand Disease

These evidence-based guidelines from the American Society of Hematology (ASH), the International Society on Thrombosis and Haemostasis (ISTH), the National Hemophilia Foundation (NHF), and the World Federation of Hemophilia (WFH) are intended to support patients, clinicians, and health care professionals in their decisions about management of VWD, a common inherited bleeding disorder.

American Society of Clinical OncologyTime to Debunk an Urban Myth? The “Abscopal Effect” With Radiation and Anti–PD-1

The term abscopal effect (from Latin, ab, meaning “away from,” and scopus, meaning “target”) was coined in 1953, specifically referring to effects of ionizing radiation outside the radiated tumor volume. Does the evidence show that, contrary to widely held perception in the field, the abscopal effect is exceedingly rare and is not clinically relevant when […]

Millennium Medical PublishingA Closer Look at Tazemetostat

In June 2020, the US Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik, Epizyme), an oral EZH2 inhibitor for the treatment of adult patients with relapsed/refractory follicular lymphoma. Clinical Advances in Hematology & Oncology takes a closer look at this new treatment through a conversation with Dr. Connie Lee Batlevi from MSKCC.

M310 Breakthrough Treatments That Will Change Medicine in 2021

At the 18th Annual 2020 Medical Innovation Summit, experts led by Will Morris, MD, executive medical director for Cleveland Clinic Innovations, and Akhil Saklecha, MD, managing director of Cleveland Clinic Ventures, recognized the top 10 medical advances for 2021. Drum roll, please! Do you agree with the choices?